Boston Scientific Buys 34% Stake in MiRus for $1.5 Billion
By Colin Kellaher
Boston Scientific has invested $1.5 billion for a roughly 34% stake in MiRus LLC, a privately held company developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases.
Boston Scientific on Monday said the MiRus deal includes an exclusive option to buy the Siegel balloon expandable transcatheter aortic valve replacement, or TAVR, system for an additional $3 billion in cash, subject to the completion of certain milestones.
The Siegel device, which isn't yet approved for commercial distribution in any country, is built on a proprietary rhenium alloy and is the first nickel-free, balloon-expandable TAVR valve intended to restore function and normal blood flow of severely narrowed aortic valves, Boston Scientific said.
The Marlborough, Mass., medical-technology company said an exercise of the purchase option would give MiRus the right to additional payments based on sales of the Siegel TAVR valve, while Boston Scientific would have an exclusive option to buy mitral and tricuspid replacement valve assets from MiRus for an additional payment.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 18, 2026 07:04 ET (11:04 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States